Actionable news
All posts from Actionable news
Actionable news in NVS: NOVARTIS AG,

GenVec says Novartis' dissolution of internal cell and gene therapy unit won't affect CGF166 program

In a regulatory filing, GenVec (NASDAQ:GNVC) reports that licensee Novartis (NYSE:NVS) remains fully committed to developing gene therapy candidate CGF166, GenVec's lead product candidate, for the treatment of...